Welcome to the third issue of Greenberg Traurig's Health & FDA Business Bulletin, a collection of timely articles written by our attorneys that are focused on significnat developments in health and FDA law. The topics in this issue span the Affordable Care Act, health care fraud and abuse, regulatory updates, and other health care topics.
Affordable Care Act
Health Care Delivery - Where Do We Go From Here?
Medicare and Medicaid Programs; Guidance on Section 1332 Waivers for State Innovation, Comments Due
Health Care Fraud & Abuse
Waivers of Certain Fraud and Abuse Laws Permitted in CJR Model
Regulatory Updates
NYS Appellate Court Upholds Executive Compensation Order and Regulations: What Happens Next?
Courts Split on Executive Order 38 Limiting Executive Compensation
NYS Court Invalidates Executive Compensation “Soft Cap” Regulation
Other
Increasing Focus on Claims Against Health Care Industry Representatives
FDA Issues Guidance for Blood Banks to Reduce Risk for Collection of Zika Infected Blood
Implications of the Zika Virus on Employment-Related Travel
How The Zika Virus Affects Employment-Related Travel
What You Need to Know About the Zika Virus
Events
ABA Health Law Section’s 2016 Antitrust in Healthcare Conference